Semin Thromb Hemost 2007; 33(4): 365-372
DOI: 10.1055/s-2007-976172
Published in 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Adverse Effects of Drugs Used to Treat Hematologic Malignancies: Surveillance Efforts from the Research on Adverse Drug Events and Reports Project

Charles L. Bennett1 , 2 , 3 , 6 , Cara C. Tigue1 , 2 , 3 , Cara Angelotta1 , 2 , 3 , June M. McKoy4 , Beatrice J. Edwards1 , 5
  • 1Veterans Affairs Center of Complex Chronic Care, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois
  • 2Division of Hematology/Oncology of the Department of Medicine, Chicago, Illinois
  • 3The Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
  • 4Division of Geriatrics of the Department of Medicine, Chicago, Illinois
  • 5Bone Health and Osteoporosis Center, Chicago, Illinois
  • 6The Kellogg School of Management, Northwestern University, Chicago, Illinois
Further Information

Publication History

Publication Date:
24 May 2007 (online)

Zoom Image

ABSTRACT

Pharmaceuticals used to treat hematologic malignancies can lead to unexpected adverse events that involve a wide range of organ systems and physiological processes. The National Cancer Institute and National Heart Lung and Blood Institute-funded Research on Adverse Drug Events and Reports (RADAR) project-a collaboration of the Robert H. Lurie Comprehensive Cancer Center, the Department of Veterans Affairs, the Northwestern University Feinberg School of Medicine, and numerous academic institutions-identifies and evaluates unexpected adverse drug reactions associated with drugs used to treat malignant disorders. This article reviews the features of the safety program maintained by the U.S. Food and Drug Administration and the RADAR program.

Crossref Cited-by logo
Zitierungen